Effect of Acute Exercise on Cognitive Functions and Blood Markers of Brain Plasticity in Regular Chronic Cannabis Users

Not Applicable

Recruiting

• Conditions: Cannabis User
• Interventions: Other: activity test

• Registration Number: NCT06081218
• Lead Sponsor: University Hospital, Lille

Brief Summary

The endocannabinoid system (ECS) is a complex endogenous signaling system made up of transmembrane cannabinoid receptors (CB1 and CB2 receptors), their endogenous lipid-derived ligands (the endocannabinoids - eCBs), and enzymes for ligand biosynthesis and degradation. Interestingly, exercise increase plasma AEA, one of the most famous endocannabinoid. This increase could be involved in exercise-induced neurogenesis and other beneficial exercise adaptations. Chronic cannabis use is associated with alteration of ECS activity. The aim of the study is to compare ECS response to exercise between chronic cannabis users and non-users.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-07-06
• Study First Submitted QC: 2023-10-06
• Study First Posted: 2023-10-13
• Study Start: 2024-05-07
• Status Verified: 2025-01
• Last Update Submitted: 2025-05-12
• Last Update Posted: 2025-05-13
• Primary Completion: 2029-05-31
• Study Completion: 2029-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Cannabis consumer group:

• Cannabis consumption > 100 times in lifetime, last exposure < 7 days, and recent exposure > 10 times in the month.
• Positive toxicological urine test for ∆-9-THC.
• Having a cannabis use disorder according to the CAST.

Healthy group:

• Negative urine toxicological test for cannabis.
• No regular cannabis use for more than 6 months once in a lifetime.
• No cannabis consumption in the 6 months preceding the study.

Exclusion Criteria

For all subjects :

• Disorders of use of other substances (alcohol, cocaine, opioid, or synthetic drugs).
• Alcohol consumption greater than 30g per day (averaged over one week) and/or alcohol abuse the week preceding the visit.
• Under medical treatment.
• Presence of diagnosed neurological disorders.
• Diagnosis of a psychotic picture entering axis I, DSM-5.
• Chronic progressive disease or in remission.
• Body mass index > 30 kg/m2 (i.e. presence of obesity).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Chronic cannabis users	activity test	-
Healthy subjects	activity test	-

Primary Outcome Measures

Name	Time	Method
Plasma endocannabinoids levels (pmol/ml)	2 weeks

Secondary Outcome Measures

Name	Time	Method
regulating hormone of endocannabinoids (plasma levels of cortisol, ng/ml)	2 weeks
Blood marker of neurogenesis and neuroplasticity (plasma levels and BDNF, pg/ml)	2 weeks
change in cerebral muscular, oxygenation (HHB), (HbO2), (Hbtot) (arbitrary unit)	2 weeks
Cognitive function (selective attention, stroop test)	2 weeks	The stroop test can be used to measure a person's selective attention capacity
Oxygen consumption (VO2) (ml/min/kg)	2 weeks

Trial Locations

Locations (1)

CHU Lille; 🇫🇷 Lille, France